Trends in liver function tests: A comparison with serum tumor markers in metastatic uveal melanoma (Part 2)

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 351-357

  Hendler, Karen ^a   Pe'er, Jacob ^a   Kaiserman, Igor ^b   Baruch, Ronen ^a   Kalickman, Inna ^a   Barak, Vivian ^a   Frenkel, Shahar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Liver function tests; Metastasis; MIA; OPN; S 100 ; TPS; Tumor markers; Uveal melanoma

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; MELANOMA INHIBITORY ACTIVITY; OSTEOPONTIN; S 100 BETA; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; PRIORITY JOURNAL; UVEA MELANOMA;

BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MELANOMA; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; OSTEOPONTIN; PEPTIDES; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE; UVEAL NEOPLASMS;

EID: 79851503507     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Shields JA and Shields CL: Diagnosis and Management of Intraocular Tumors. St. Louis, Mosby, 1983.
2. Mooy CM and DeJong PTVM: Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41: 215-228, 1996. (Pubitemid 26424326)
3. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123: 1639-1643, 2005.
4. McLean IW: The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch Pathol Anat 422: 433-437, 1993.
5. Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 124: 1684-1693, 2006.
6. Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Negrier S and Grange JD: Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 12: 1-7, 2005.
7. Singh AD and Borden EC: Metastatic uveal melanoma. Ophthalmol Clin N Am 18: 143-150, 2005. (Pubitemid 40348818)
8. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O and Pe'er J: Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 93: 1042-1046, 2009.
9. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Green DL, Hawkins BS, Hayman J, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM and Thoma J: Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22: 2438-2444, 2004. (Pubitemid 41115402)
10. Kaiserman I, Amer R and Pe'er J: Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137: 236-243, 2004. (Pubitemid 38220994)
11. Eskelin S, Pyrhonen S, Summanen P, Prause JU and Kivela T: Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85: 1151-1159, 2004.
12. Hicks C, Foss AJE and Hungerford JL: Predictive power of screening tests for metastasis in uveal melanoma. Eye 12: 945-948, 1998.
13. Zakka KA, Foos RY, Omphroy CA and Straatsma BR: Malignant melanoma: analysis of an autopsy population. Ophthalmology 87: 549-56, 1980. (Pubitemid 10066563)
14. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Sefty S, Maniotis AJ, Folberg R and Pe'er J: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 47: 802-806, 2006. (Pubitemid 46768309)
15. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J: Serum markers to detect metastatic uveal melanoma. Anticancer Res 27: 1897-1900, 2007.
16. Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin AY, Kalickman I, Baumann NA, Pe'er J, Maniotis AJ, Folberg R: Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. Invest Ophthalmol Vis Sci 48: 4399-4402, 2007. (Pubitemid 351260951)
17. Missotten GS, Korse CM, van Dehn C, Linders TC, Keunen JE, Jager MJ and Bonfrer JM: S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol 28: 63-69, 2007. (Pubitemid 46328593)
18. Reiniger IW, Wolf A, Welge-Lussen U, Mueller AJ, Kampik A and Schaller UC: Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 143: 705-707, 2007. (Pubitemid 46452513)
19. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R and Schaller UC: Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223: 239-243, 2009.
20. Barak V, Kaiserman I, Frenkel S, Hendler K and Pe'er J: Dynamics of serum biomarkers and their role in predicting metastatic uveal melanoma. Anticancer Res 31: 345-350, 2011.
21. Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A and Mueller AJ: Melanoma inhibitory activity (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefe's Arch Clin Exp Ophthalmol 243: 1161-1166, 2005.
22. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G and Stieber P: Tumor markers in breast cancer - European Group on Tumor Markers recommendations. Tumour Biol 26: 281-293, 2005. (Pubitemid 41619458)
23. Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P, Sturgeon C and Einarsson R: The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 13: 10-15, 1998. (Pubitemid 28356504)
24. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R and Bosserhoff A: Comparison of two prognostic markers for malignant melanoma: MIA and S-100β. Tumour Biol 22: 54-58, 2001.
25. Molina R, Navarro J, Fillela X, Castel T and Ballesta AM: S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23: 39-44, 2002. (Pubitemid 34225020)